Industry News

George Clinical Client Noxopharm Announces Chemotherapy Enhancement Program Expansion

Noxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]

Read More

April 20th, 2019

George Clinical Congratulates Parent Company The George Institute For Global Health For Securing $12 Million To Tackle Worlds Biggest Killers

[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock […]

Read More

February 12th, 2019

Taiwan’s Pragmatic Timelines Make it a ‘Top-Tier’ Country for MRCTs

George Clinical welcomes The Taiwan Food and Drug Administration’s (TFDA) recent clarified timelines for approval of a general Clinical Trial Authority (CTA) at 45 calendar days. The announcement, released by the TFDA in October, adds to the suite of attractive options to expedite clinical trial regulatory approval timelines in Taiwan. This includes the existing 15 […]

Read More

January 8th, 2019

Established Investigator Networks Are Central to the Strength of the Clinical Trial Environment

The importance of securing strong, long-standing investigator networks with leading research hospitals and clinics is critical to the continued growth of the clinical trial environment in countries such as Taiwan, says Evon Hui, Head of Business Operations, East Asia. Over the past 15 years, George Clinical has cultivated an enviable network of MOUs that have […]

Read More

January 6th, 2019

George Clinical Scientific Leader Jason Chandler Sees Approval of New Therapy

George Clinical welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and George Clinical Scientific Leader, Dr. Jason Chandler of West Cancer Center. Car-T therapies are at the cutting edge of treatment for a range of cancers. The recent announcement by the FDA, West Cancer […]

Read More

January 4th, 2019

Heart Health Research Center provides extensive research training and investigator networks to leading CRO George Clinical

Beijing, November 13, 2018 – George Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart Health Research Center (HHRC), further developing the depth and quality of investigator networks. The HHRC, a collaborative initiative developed by Cardio Union, an emerging multi-disciplinary healthcare organization and the […]

Read More

December 6th, 2018

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]

Read More

August 15th, 2018
Changes in china

There has never been a better time to consider China as part of your development strategy!

In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the 12th April 2018. From 1 May 2018, the import tariff of all common drugs including anticancer drugs, alkaloids with anticancer effects and the imported Chinese patent […]

Read More

April 19th, 2018
China

Significant changes ahead for drug development in China?

Significant changes are ahead for clinical research in China. The Public Consultation Notice for Policies to Encourage Innovation and Reform in Regulation of Drug and Medical Device Clinical Testing was released by the CFDA on 11 May, 2017. These proposed changes herald an exciting new era for drug and device development. If implemented in full, […]

Read More

June 16th, 2017
Taiwan

Taiwan: The Clinical Trials Gateway to China?

Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more formalized with China, than Taiwan, Taiwan has the right environment and population to make the possibility of greater regulatory cohesion with its giant neighbour, […]

Read More

March 15th, 2017
George Clinical

customerservice@georgeclinical.com

Profits from George Clinical support the work of The George Institute for Global Health.

Join our Mailing List

Add George Clinical to your network